Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLI850 is an osmotic laxative combination developed by Braintree Laboratories for bowel cleansing prior to colonoscopy. The product is a hybrid formulation that combines half-doses of an oral sulfate solution (comprising sodium sulfate, potassium sulfate, and magnesium sulfate) with polyethylene glycol 3350 (PEG-3350). This combination is intended to facilitate colonic evacuation by increasing the osmotic pressure within the intestinal lumen, thereby promoting water retention and bowel movements. BLI850 was designed to optimize the balance between cleansing efficacy and patient tolerability compared to standard full-dose sulfate or high-volume PEG preparations. It was developed under IND 102894 and evaluated in Phase 3 clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BLI850.